Potential Metabolic Biomarkers to Identify Interstitial Lung Abnormalities

Area of Science:

• Biochemistry
• Pulmonology
• Metabolomics

Background:

• Early diagnosis of interstitial lung abnormalities (ILAs) is crucial for effective management.
• Identifying sensitive biomarkers in peripheral blood can simplify early detection.
• Understanding the pathogenesis of ILAs is essential for developing targeted therapies.

Purpose of the Study:

• To identify serum metabolic biomarkers for interstitial lung abnormalities (ILAs).
• To elucidate the pathogenesis of ILAs through metabolic pathway analysis.
• To establish a method for early diagnosis of subclinical disease states.

Main Methods:

• Serum metabolic profiling using liquid chromatography-quadrupole time-of-flight mass spectrometry.
• Analysis of three subject groups: healthy, ILAs, and healthy progressing to ILAs.
• Prediction and verification of metabolic biomarkers and associated pathways.

Main Results:

• Five serum metabolites (phosphatidylcholine, phosphatidic acid, betaine aldehyde, phosphatidylethanolamine, 1-acylglycerophosphocholine) identified as sensitive and reliable ILAs biomarkers.
• Up-regulation of phosphatidylcholine, phosphatidic acid, betaine aldehyde, and phosphatidylethanolamine observed.
• Down-regulation of 1-acylglycerophosphocholine observed in ILAs patients.
• Perturbations in RhoA signaling, mTOR/P70S6K signaling, and phospholipase C signaling pathways implicated in ILAs pathogenesis.

Conclusions:

• Serum metabolic profiling can identify sensitive biomarkers for early interstitial lung abnormalities (ILAs) detection.
• Specific metabolite alterations and pathway dysregulations are associated with ILAs pathogenesis.
• This approach offers a template for early diagnostic marker discovery in subclinical diseases.